Incidence of toxicity was high (51%).Conclusion OS improved in this high-risk group over the years, especially after introduction of new treatment modalities. However, early death rate remains high, illustrating the need for more effective treatment.BACKGROUND Accurate awareness of the prognosis is an important factor in the treatment decision of patients with advanced cancer; however, prognostic disclosure is still subject to debate because it can reduce patient's satisfaction and increase depression. AIM The purpose of this study is to assess whether patients' prognostic awareness is associated with decreased quality of life (QoL) or increased depressive mood in patients with advanced cancer. DESIGN AND PARTICIPANTS In this cohort study, 386 patients with advanced cancer were recruited across 3 periods from December 2016 to August 2018. The outcome of this study was a change in QoL and depression according to the patients' prognostic awareness at baseline, 3 months, and 6 months. RESULTS This study found significant differences in changes of QoL based on patients' prognostic awareness. From baseline to 3 months, emotional functioning (P = .039), pain (P = .042), existential well-being (P = .025), and social support (P = .038) subscale scores improved significantly more in those with lack of prognostic awareness. Over 6 months, the group without prognostic awareness improved significantly in terms of physical functioning (P = .037), emotional functioning (P = .002), nausea/vomiting (P = .048), and constipation (P = .039) subscale scores and existential well-being scores (P = .025). No significant difference between the groups was found in terms of depression. CONCLUSION Accurate prognostic awareness may pose harm and may provide no additional benefits in terms of QoL and mood among patients with advanced cancer for a short period of time.BACKGROUND Self-application of topicals on the back can be challenging. https://www.selleckchem.com/products/Trichostatin-A.html OBJECTIVE The aim was to assess topical back coverage using commercially available back applicators. MATERIALS AND METHODS Ten subjects applied sunscreen to their back using their hands and then with 3 back applicators (large foam tip, small foam tip, roller tip). The amount of lotion used and the time it took to perform the application were recorded. The resulting distribution of sunscreen was assessed with a Wood's lamp; the area covered fluoresced less than the uncovered skin. Images were captured and then analyzed using an automated thresholding technique. RESULTS Subjects applied more lotion when using the large foam tip (7.58 g, 95% CI 6.47-8.70 g; P less then .004) and small foam tip (7.46 g, 95% CI 6.35-8.57 g; P less then .006) applicators compared to hands alone (6.22 g, 95% CI 5.10-7.33 g). Application time was longer with the small foam tip applicator (113.4 s, 95% CI 96.7-130.1 s) relative to hand application (78.7 s, 95% CI 62-95.4 s) (P less then .03). Coverage of the back was higher for the large foam tip (84.8%, 95% CI 78.4%-91.3%; P less then .03), small foam tip (88.0%, 95% CI 81.6%-91.5%; P less then .006), and roller tip (84.3%, 95% CI 77.9%-90.8%; P less then .04) applicators compared to hand application (71.5%, 95% CI 65%-78%). The middle back tended to have less coverage when applying with the hands. CONCLUSIONS Topical coverage of the back is improved with the use of applicator devices during self-application.Objective To review the safety, efficacy, and administration of intranasal (IN) glucagon for the management of hypoglycemia. Data Source A literature search of PubMed/MEDLINE (1995 to November 2019) using the terms intranasal glucagon, nasal glucagon, glucagon, hypoglycemia treatment, and hypoglycemia management was completed. Study Selection and Data Extraction English-language studies evaluating IN glucagon were evaluated. Data Synthesis IN glucagon is a newly approved product for the treatment of hypoglycemia in patients with diabetes, 4 years and older. Administered as a 3-mg dose, it was shown to be noninferior to intramuscular (IM) glucagon. In comparison trials, more than 98% of hypoglycemic events were treated successfully with IN glucagon in both pediatric and adult patients. In simulated and real-world studies, IN glucagon was administered in less than a minute for the majority of scenarios. IM glucagon took longer to administer, ranging from 1 to 4 minutes, and often, patients did not receive the intended full dose. Nausea and vomiting, known adverse events for glucagon, as well as local adverse events were most commonly reported with IN glucagon. Relevance to Patient Care and Clinical Practice IN glucagon is safe, effective, easy to use, and does not require reconstitution prior to use, which can lead to faster delivery in a severe hypoglycemic event. It does not require age- or weight-based dosing. This delivery method offers an option for someone who fears needles or is uncomfortable with injections. Conclusion IN glucagon is a safe, effective, easy to use, needle-free treatment option for severe hypoglycemia.Background and objectives Social anxiety disorder is a common comorbidity in psychotic disorders and impacts significantly on functioning and recovery. Conflicting theories and evidence exist on its relationship with other psychopathologies. This study examined this complex network of relationship using path analysis.Design Clinical assessment and self-report in a cross-sectional consecutive outpatient sample.Methods Face-to-face interviews were conducted in 137 outpatients with early psychosis. A theoretical model of relationship between social anxiety, insight, persecutory delusions, ideas of reference, negative symptoms, and depression was tested using path analysis.Results Clinically significant social anxiety was observed in 45% of this sample. The final model suggested a direct link between ideas of reference (standardized path coefficient, β = 0.26, p  less then  0.002) and negative symptoms (β = 0.29, p  less then  0.001) to social anxiety. Insight was related to both persecutory delusions and negative symptoms but had no direct relationship with social anxiety. The model has excellent goodness-of-fit (Chi-square 6.62, comparative fit index 1.00, root mean square error of approximation 0.00).Conclusions This model provided a new framework for understanding the complex interplay between psychosis symptoms and social anxiety, which may be unique to outpatients with early psychosis and require further confirmatory research and targeted intervention strategies.